Login to Your Account



Hana Paying Up To $42M For Inex’s Cancer Drugs

By Randall Osborne


Monday, March 20, 2006
A week after finishing pivotal trials with its nausea drug, Hana Biosciences Inc. signed a letter of intent to double its pipeline of compounds by licensing worldwide rights to three targeted chemotherapeutics from Inex Pharmaceuticals Corp. in a stock-and-cash deal worth up to $42 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription